You are hereJanuary 4, 2021
Synergistic Treg and MSC Treatment of TBI
A new study from researchers led by Scott D. Olson and Charles S. Cox, Jr. (University of Texas Health Science Center at Houston, Houston, Texas, USA) now demonstrates that human regulatory T cell (Treg) and mesenchymal stem cell (MSC) combination therapy displays improved potency and attenuation of inflammatory responses by activated rat immune cells in comparison to monotherapy. During in vivo analyses, Caplan et al. also discovered that only staggered Treg/MSC therapy significantly reduced microgliosis after traumatic brain injury (TBI), indicating that both the combination and timing of cell therapy have significant effects. For more info, see STEM CELLS now!